Evidence map›Paper›PMID 42883968›Full record

ArticleInternational journal of molecular sciences2026

Integrated Molecular, Clinicopathological and Immune Profiling of Non-Small Cell Lung Cancer: The MONREPOS Hellenic Cooperative Oncology Group (HeCOG) Study (HE_2TR/13).

Konstantinos Efthymiadis, Chrysa Soteriou, Vassiliki Kotoula, Kyriaki Papadopoulou, Abraham Pouliakis, Sofia Lampaki, Anna Goussia, Elena Fountzilas, Soultana Meditskou, Mattheos Bobos and 16 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Konstantinos EfthymiadisDepartment of Medical Oncology, Papageorgiou Hospital, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, 56403 Thessaloniki, Greece.
Chrysa SoteriouMedicover Genetics, 2409 Nicosia, Cyprus.ORCID 0000-0002-2808-1215
Vassiliki KotoulaDepartment of Pathology, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Kyriaki PapadopoulouLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, 54124 Thessaloniki, Greece.ORCID 0000-0003-0389-4209
Abraham Pouliakis2nd Department of Pathology, Attikon University Hospital, National and Kapodistrian University of Athens, 12461 Athens, Greece.ORCID 0000-0002-0074-3619
Sofia LampakiLung Cancer Oncology Unit, Pulmonary Department, G. Papanikolaou Hospital, Aristotle University of Thessaloniki, 57010 Thessaloniki, Greece.
Anna GoussiaDepartment of Pathology, Ioannina University Hospital, 45500 Ioannina, Greece.
Elena FountzilasDepartment of Medical Oncology, St Luke's Clinic, Panorama, 55236 Thessaloniki, Greece.
Soultana MeditskouLaboratory of Histology and Embryology, Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Mattheos BobosLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, 54124 Thessaloniki, Greece.ORCID 0000-0001-5662-9201
Konstantinos KyritsisInstitute of Applied Biosciences, Centre for Research and Technology Hellas, 60361 Thessaloniki, Greece.ORCID 0000-0001-8035-341X
Christos LemesiosMedicover Genetics, 2409 Nicosia, Cyprus.
Epaminontas SamantasThird Department of Medical Oncology, Agii Anargiri Cancer Hospital, 14564 Athens, Greece.
Evangelos SarrisFourth Oncology Department and Comprehensive Clinical Trials Center, Metropolitan Hospital, 18547 Athens, Greece.
George PentheroudakisDepartment of Medical Oncology, Medical School, University of Ioannina, 45500 Ioannina, Greece.
Dimitrios BafaloukosFirst Department of Medical Oncology, Metropolitan Hospital, 18547 Athens, Greece.
Dimitrios PectasidesOncology Section, Second Department of Internal Medicine, Hippokratio Hospital, 11527 Athens, Greece.
Paris A KosmidisSecond Department of Medical Oncology, Hygeia Hospital, 15123 Athens, Greece.ORCID 0009-0003-1478-0087
Flora ZagouriDepartment of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0001-7153-6556
Dionysis SpyratosDepartment of Respiratory Medicine, "G. Papanikolaou" General Hospital of Thessaloniki, 57010 Thessaloniki, Greece.
Eleni TimotheadouDepartment of Medical Oncology, Papageorgiou Hospital, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, 56403 Thessaloniki, Greece.ORCID 0000-0003-2545-8926
Prodromos HytiroglouDepartment of Pathology, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0003-3412-2914
Alexia EliadesMedicover Genetics, 2409 Nicosia, Cyprus.ORCID 0000-0001-8459-7163
George KoumbarisMedicover Genetics, 2409 Nicosia, Cyprus.
George FountzilasLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, 54124 Thessaloniki, Greece.ORCID 0000-0001-8045-2186
Helena LinardouFourth Oncology Department and Comprehensive Clinical Trials Center, Metropolitan Hospital, 18547 Athens, Greece.

Funding

Hellenic Society of Medical Oncology (HeSMO) HE_2TR/13
6 · The paper itself

Abstract

Integrated assessment of tumour genomics and immune biomarkers may improve prognostic stratification in non-small cell lung cancer (NSCLC). We examined the distribution and prognostic relevance of somatic pathogenic/likely pathogenic variants (PVs), somatic copy-number alterations (SCNAs), programmed death-ligand 1 (PD-L1) expression and tumour-infiltrating lymphocytes (TILs) in a multicentre cohort. This retrospective, multicentre study included 367 unselected patients with histologically confirmed NSCLC treated at 19 centres in Greece between 2000 and 2020. Targeted next-generation sequencing (NGS) was performed in 267 tumours; PD-L1 tumour proportion score (TPS) and haematoxylin and eosin (H&E)-based TIL density were evaluated in 298 and 352 tumours, respectively. Overall survival (OS) was assessed using Kaplan-Meier and multivariable Cox regression analyses.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAgedAged, 80 and overB7-H1 AntigenBiomarkers, TumorDNA Copy Number VariationsFemaleHigh-Throughput Nucleotide SequencingHumansLymphocytes, Tumor-InfiltratingMaleMutationPrognosisRetrospective StudiesB7-H1 AntigenBiomarkers, TumorCD274 protein, humanco-mutationsmolecular profilingnon-small cell lung cancerPD-L1prognosistumour-infiltrating lymphocytes

Identifiers

PMID42883968
PMCPMC13665066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.